(CercleFinance.com) – Gimv announced on Wednesday the creation of a platform entirely dedicated to its investments in the life sciences sector.
This platform – the fifth in its portfolio after those already devoted to consumption, health, smart industry and sustainable cities – will initially combine its holdings in the companies Precirix, ImCheck and ImmunOs.
With this project, Gimv says it wants to increase the entry ticket for its equity investments, now aiming for initial investments of between 10 and 15 million euros in the companies selected.
Its objective is to double the size of its portfolio in the field to eventually invest in around twenty companies.
In its press release, Gimv explains that it can rely on proven expertise in the field, which saw it be one of the first investors to enter the capital of Ablynx and invest in Covagen before its sale to Johnson & Johnson. .
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
